The Role of Inflammatory Biomarkers in PIPAC: Predicting Survival and Treatment Completion in Patients with Peritoneal Metastasis.

ABSTRACT: Introduction: Appropriate patient selection is essential for optimising outcomes in individuals with peritoneal metastasis (PM) undergoing treatment with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC). This study investigated the prognostic value of pretreatment inflammatory biomarkers and explored their ability to predict the possibility of completion of three or more PIPAC treatments. Method: This observational study analysed prospectively collected data from patients with PM of gastrointestinal or ovarian origin enrolled in the PIPAC OPC-1 or OPC-2 studies between March 2015 and January 2022. Six biomarkers were examined: Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio, Systemic Immune-Inflammation Index (SII), C-reactive protein, modified Glas

SUBMITTER: Roensholdt S 

PROVIDER: S-EPMC12719556 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature